JOP20210323A1 - ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 - Google Patents

ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3

Info

Publication number
JOP20210323A1
JOP20210323A1 JOP/2021/0323A JOP20210323A JOP20210323A1 JO P20210323 A1 JOP20210323 A1 JO P20210323A1 JO P20210323 A JOP20210323 A JO P20210323A JO P20210323 A1 JOP20210323 A1 JO P20210323A1
Authority
JO
Jordan
Prior art keywords
heavy chain
chain antibodies
antibodies binding
multispecific
multispecific heavy
Prior art date
Application number
JOP/2021/0323A
Other languages
English (en)
Inventor
Rangaswamy Udaya
Iyer Suhasini
Prabhakar Kirthana
Trinklein Nathan
Ugamraj Harshad
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of JOP20210323A1 publication Critical patent/JOP20210323A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن ارتباط أجسام مضادة بشرية ثقيلة السلسلة ومتعددة النوعية (على سبيل المثال، UniAbsTM) بـ CD22 وCD3، كما يتعلق بطرق تحضير تلك الأجسام المضادة، وتركيبات، بما في ذلك تركيبات صيدلية، تشتمل على تلك الأجسام المضادة، واستخدامها في علاج اضطرابات تتميز بالتعبير الوراثي عن CD22.
JOP/2021/0323A 2019-06-14 2020-06-12 ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 JOP20210323A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861708P 2019-06-14 2019-06-14
PCT/US2020/037566 WO2020252366A1 (en) 2019-06-14 2020-06-12 Multispecific heavy chain antibodies binding to cd22 and cd3

Publications (1)

Publication Number Publication Date
JOP20210323A1 true JOP20210323A1 (ar) 2023-01-30

Family

ID=71409534

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0323A JOP20210323A1 (ar) 2019-06-14 2020-06-12 ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3

Country Status (21)

Country Link
US (1) US11905326B2 (ar)
EP (1) EP3983438A1 (ar)
JP (1) JP2022537931A (ar)
KR (1) KR20220020810A (ar)
CN (1) CN114206927A (ar)
AR (1) AR119746A1 (ar)
AU (1) AU2020291938A1 (ar)
BR (1) BR112021024956A2 (ar)
CA (1) CA3140816A1 (ar)
CL (1) CL2021003343A1 (ar)
CO (1) CO2021016907A2 (ar)
CR (1) CR20210622A (ar)
EA (1) EA202290054A1 (ar)
EC (1) ECSP21090414A (ar)
IL (1) IL288749A (ar)
JO (1) JOP20210323A1 (ar)
MX (1) MX2021015337A (ar)
PE (1) PE20220575A1 (ar)
TW (1) TW202108628A (ar)
UY (1) UY38748A (ar)
WO (1) WO2020252366A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
EP4050034B1 (en) * 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
BR112019026803A2 (pt) 2017-06-20 2020-06-30 Teneoone, Inc. anticorpos apenas de cadeia pesada anti-bcma
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
JP7486421B2 (ja) 2017-12-22 2024-05-17 テネオバイオ， インコーポレイテッド Ｃｄ２２に結合する重鎖抗体
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
PT1141274E (pt) 1999-01-07 2004-02-27 Zymogenetics Inc Receptor soluvel br43x2 e metodos para sua utilizacao
KR100897082B1 (ko) 1999-08-17 2009-05-14 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
BR0110610A (pt) 2000-04-11 2003-04-29 Genentech Inc Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
PL1673398T3 (pl) 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
HUE025328T2 (en) 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
EP3272770B1 (en) 2004-07-22 2023-12-20 Erasmus University Medical Center Rotterdam Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain
ES2498794T3 (es) 2005-02-18 2014-09-25 Medarex, L.L.C. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG174779A1 (en) 2005-09-12 2011-10-28 Novimmune Sa Anti-cd3 antibody formulations
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
KR20080090414A (ko) 2005-12-06 2008-10-08 도만티스 리미티드 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2008016431A2 (en) 2006-07-29 2008-02-07 Robert Lamar Bjork Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
RS58217B1 (sr) 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
NZ581396A (en) 2007-06-01 2012-07-27 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2009294416B2 (en) 2008-09-19 2014-05-22 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
BRPI0919841A2 (pt) 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
CN102164961B (zh) 2008-10-01 2014-04-16 安进研发（慕尼黑）股份有限公司 种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体
PT2352763E (pt) 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
US9034324B2 (en) 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN102770456B (zh) * 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
BR112013028779B8 (pt) 2011-05-27 2021-04-20 Glaxo Group Ltd proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR20150004856A (ko) 2012-04-20 2015-01-13 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd3 결합 폴리펩타이드
CA2871764A1 (en) 2012-04-26 2013-10-31 Gerhard Frey Anti-cd22 antibodies
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
CN103546517B (zh) 2012-07-16 2018-03-20 腾讯科技（深圳）有限公司 网络信息推送系统和方法
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013358958B2 (en) 2012-12-14 2018-09-20 Open Monoclonal Technology, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
NZ719784A (en) 2013-10-31 2022-02-25 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
NZ720161A (en) 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3461848B1 (en) 2014-10-22 2023-10-11 Crescendo Biologics Limited Transgenic mice
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
RU2747011C2 (ru) 2014-11-20 2021-04-23 Ф.Хоффманн-Ля Рош Аг Общие легкие цепи и способы их применения
PL3628687T3 (pl) 2014-12-12 2022-03-21 2Seventy Bio, Inc. Chimeryczne receptory antygenowe bcma
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CN104710528B (zh) 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
EP3297729A4 (en) 2015-05-20 2019-04-10 Janssen Biotech, Inc. ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAINS AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGICAL TUMORS
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
LT3337824T (lt) 2015-08-17 2020-09-25 Janssen Pharmaceutica Nv Anti-bcma antikūnai, bispecifinės antigeną surišančios molekulės, kurios suriša bcma ir cd3, ir jų panaudojimas
EP3374397A2 (en) 2015-11-10 2018-09-19 University Medical Center Hamburg - Eppendorf Antigen-binding polypeptides directed against cd38
IL260958B1 (en) 2016-02-03 2024-07-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
AU2017316604A1 (en) 2016-08-24 2019-04-11 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
EP4050034B1 (en) * 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
JP7254699B2 (ja) 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
BR112019026803A2 (pt) 2017-06-20 2020-06-30 Teneoone, Inc. anticorpos apenas de cadeia pesada anti-bcma
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SG11201913175TA (en) 2017-06-30 2020-01-30 The United States Of America As Represented By The Secretary Anti-b-cell maturation antigen chimeric antigen receptors with human domains
RU2020112490A (ru) 2017-09-13 2021-10-13 Тенеобио, Инк. Антитела из тяжелых цепей, связывающиеся с эктоферментами
US20200262920A1 (en) 2017-10-12 2020-08-20 Amphivena Therapeutics Inc. Dosing regimen for cd3 binding proteins
JP7486421B2 (ja) * 2017-12-22 2024-05-17 テネオバイオ， インコーポレイテッド Ｃｄ２２に結合する重鎖抗体
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
AU2019275284A1 (en) 2018-05-24 2021-01-14 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
MX2021000708A (es) 2018-07-20 2021-03-25 Teneobio Inc Anticuerpos de cadena pesada que se unen al cd19.
CA3113057A1 (en) 2018-09-21 2020-03-26 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
KR20220114559A (ko) 2019-12-18 2022-08-17 테네오포, 인코포레이티드 Cd38에 결합하는 중쇄 항체
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
EP4149628A1 (en) 2020-05-11 2023-03-22 Janssen Biotech, Inc. Methods for treating multiple myeloma
JP2023532129A (ja) 2020-06-30 2023-07-26 テネオバイオ， インコーポレイテッド Ｂｃｍａに結合する多重特異性抗体
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
EP4298129A1 (en) 2021-02-26 2024-01-03 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
BR112023020450A2 (pt) 2021-04-06 2024-01-23 Teneobio Inc Anticorpos anti-cd19 e estruturas car-t
PE20240656A1 (es) 2021-04-16 2024-04-04 Teneobio Inc Anticuerpos anti-cd20 y estructuras car-t
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen

Also Published As

Publication number Publication date
CO2021016907A2 (es) 2022-01-17
WO2020252366A1 (en) 2020-12-17
CN114206927A (zh) 2022-03-18
AR119746A1 (es) 2022-01-05
IL288749A (en) 2022-02-01
PE20220575A1 (es) 2022-04-20
US11905326B2 (en) 2024-02-20
KR20220020810A (ko) 2022-02-21
EP3983438A1 (en) 2022-04-20
BR112021024956A2 (pt) 2022-01-25
EA202290054A1 (ru) 2022-03-25
US20210047402A1 (en) 2021-02-18
CL2021003343A1 (es) 2022-07-15
JP2022537931A (ja) 2022-08-31
ECSP21090414A (es) 2022-01-31
MX2021015337A (es) 2022-01-18
UY38748A (es) 2021-01-29
CR20210622A (es) 2022-06-27
AU2020291938A1 (en) 2022-01-20
CA3140816A1 (en) 2020-12-17
TW202108628A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
JOP20210253A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12020552229A1 (en) Il-11ra antibodies
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
CR20230149A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539)
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2022002682A (es) Anticuerpos anti-cd73.
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t
CR20230525A (es) Anticuerpos anti-cd20 y estructuras car-t
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.